Quick answers
- What is Ceftriaxone sodium used for?
- The FDA-approved label (Ceftriaxone and Dextrose, B. Braun Medical Inc., January 13, 2022) says: “Ceftriaxone for Injection and Dextrose Injection is indicated for the treatment of the following infections when caused by susceptible bacteria. Ceftriaxone for Injection and Dextrose Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible isolates of the designated bacteria: Lower Respiratory Tract Infections; Skin and Skin Structure Infections …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Ceftriaxone sodium have a boxed warning?
- No. None of the 34 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Ceftriaxone sodium?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Ceftriaxone sodium been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started October 19, 2016 (Class III). A recall usually concerns specific lots, not every product.
- Who makes Ceftriaxone sodium?
- 17 companies list prescription products of Ceftriaxone sodium in the FDA NDC Directory, including Hospira, Inc., WG Critical Care, LLC and Hikma Pharmaceuticals USA Inc..
What Ceftriaxone sodium is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Ceftriaxone for Injection and Dextrose Injection is indicated for the treatment of the following infections when caused by susceptible bacteria. Ceftriaxone for Injection and Dextrose Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible isolates of the designated bacteria: Lower Respiratory Tract Infections; Skin and Skin Structure Infections …
— FDA label: Ceftriaxone and Dextrose, B. Braun Medical Inc., effective January 13, 2022. Read the full label on DailyMed →
The FDA has 34 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 34 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Injection, powder, for solution · Injection, solution |
|---|---|
| Route | Intravenous · Intramuscular |
| Prescription products | 55 in the FDA NDC Directory |
| Brand names | Ceftriaxone and Dextrose |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| ceftriaxone sodium 1 g injection, powder, for solution | Generic | $1.18–$1.46 per unit 10 packages, lowest to highest |
| ceftriaxone sodium 2 g injection, powder, for solution | Generic | $2.79 per unit |
| ceftriaxone sodium 250 mg injection, powder, for solution | Generic | $0.8622 per unit |
| ceftriaxone sodium 500 mg injection, powder, for solution | Generic | $1.29–$1.86 per unit 6 packages, lowest to highest |
NADAC list of November 4, 2026; these prices took effect between February 18, 2026 and October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Hospira, Inc.13 products
- WG Critical Care, LLC6 products
- Hikma Pharmaceuticals USA Inc.5 products
- Sportpharm LLC5 products
- Apotex Corp.5 products
- Sandoz Inc5 products
- Proficient Rx LP4 products
- Qilu Pharmaceutical Co., Ltd.4 products
- A-S Medication Solutions4 products
- Sagent Pharmaceuticals2 products
- Baxter Healthcare Company2 products
- Civica, Inc.2 products
- B. Braun Medical Inc.2 products
- Fresenius Kabi USA, LLC1 product
- Samson Medical Technologies LLC1 product
- Asclemed USA, Inc.1 product
- Remedyrepack Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA050796 CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER | B Braun | April 20, 2005 | 12, latest January 13, 2022 2022: Labeling · 2021: Labeling · 2020: Labeling |
Generic approvals (11)
- ANDA065204Sandoz Inc · May 3, 2005
- ANDA065169Sandoz · May 9, 2005
- ANDA065168Sandoz · May 17, 2005
- ANDA065224Baxter Hlthcare · August 23, 2005
- ANDA065342Hikma Farmaceutica · January 10, 2008
- ANDA065328Acs Dobfar · July 24, 2008
- ANDA065329Acs Dobfar · July 24, 2008
- ANDA090057Samson Medcl · April 25, 2014
- ANDA203702Qilu Antibiotics · June 29, 2016
- ANDA090701Hikma · October 4, 2017
- ANDA209218Qilu Antibiotics · October 17, 2018
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
October 19, 2016 · Class III · Terminated · D-0145-2017
Labeling: Missing Label
Ceftriaxone for Injection, USP, 1 gram, 10 Single use Vials, Rx only, For IM or I.V. Use, Manufactured by: Sandoz GMbH for Hospira Worldwide, Inc., Lake Forest, Il 60045, USA, Made in Austria, NDC 0409-7332-01 — Sandoz Inc
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Ceftriaxone and Dextrose, B. Braun Medical Inc., effective January 13, 2022; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →